2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theHereditary Angioedema Market?

The expansion of the hereditary angioedema market is anticipated to be fueled by the escalating prevalence of rare or orphan diseases, which are health conditions impacting a minor portion of the populace. The rising incidence of such diseases is attributed to multiple factors like advancements in medical studies, demographic shifts in population, and the effects of the environment. The imperative case of hereditary angioedema showcases the urgency for specialized care and awareness due to its potentially lethal swelling incidents. Given its infrequent occurrence and genetic basis, prompt diagnosis and targeted treatments are critical to effectively manage the disease and enhance patient health outcomes. For example, as per the data from Rare Disease Advisor, a US-based digital resource enterprise for healthcare professionals, the frequency of HAE impacts roughly 1 individual from every 50,000, with prevalence estimated to range between 1 in 10,000 to 1 in 150,000. In the U.S., yearly there are about 15,000 to 30,000 emergency room visits due to HAE incidents. Consequently, the augmenting prevalence of rare diseases is propelling growth in the hereditary angioedema market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

#What Long-Term Growth Rate is Expected for theHereditary Angioedema Market Between 2025 and 2034?

In recent times, the market for hereditary angioedema has witnessed robust growth. It is projected to expand from a value of $2.62 billion in 2024 to $2.84 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.7%. This unprecedented growth in the historic period is a result of several factors such as the rising incidence of hereditary angioedema, increased investments in R&D activities, a surge in the number of drug approvals, an increase in product clearance, and burgeoning disposable income.

Anticipated robust expansion is expected for the hereditary angioedema market size in the coming years. The market is predicted to escalate to $3.93 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. Factors contributing to the projected advancement during this period include the increasing occurrence of uncommon diseases, rising medical costs, augmented support from non-profit organizations, growing knowledge about hereditary angioedema, and increased recognition for early diagnosis. Notable trends over the forecast period encompass technological evolution, invention of innovative therapies, introduction of new medications, sophisticated diagnostic tools, and progress in genetic testing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002

What Key Market Trends and Innovations Are Shaping the Future of theHereditary Angioedema Industry?

Leading businesses within the hereditary angioedema market are channeling their efforts towards crafting pioneering products, like oral plasma kallikrein inhibitors, aiming to present more effective and convenient on-demand solutions for affected individuals. The said inhibitors function by impeding plasma kallikrein, consequently stopping the overproduction of bradykinin, making them an ideal way to treat hereditary angioedema. For instance, KalVista Pharmaceuticals, Inc., a pharmaceutical corporation based in the US, in September 2024, declared the FDA approval of its new drug application (NDA) for sebetralstat. This under-review oral plasma kallikrein inhibitor is custom-made for on-demand hereditary angioedema (HAE) treatment, and is suitable for pediatric and adult patients aged 12 and above. Aiming at curtailing plasma kallikrein activity, Sebetralstat ushers a creative treatment methodology. The sanction of the NDA marks a significant milestone into the prospective sanctioning and commercialization.

Which Companies Are Leading the Charge in Expanding theHereditary Angioedema Market Growth?

Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

How is the Global Hereditary Angioedema Market Segemented?

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels, Reduced C1-Inhibitor Function

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

Which Geographics are Influencing the Growth of the Hereditary Angioedema Market?

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2025, By The Business Research Company:

Hereditary Cancer Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report

Hereditary Angioedema Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: